Managing Anticoagulation in Patients Receiving Implantable Cardiac Devices

References

• Mond HG , ProclemerA . The 11th world survey of cardiac pacing and implantable cardioverter-defibrillators: calendar year 2009 a World Society of Arrhythmia’s project . Pacing Clin. Electrophysiol.34 ( 8 ), 1013 – 1027 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Nielsen JC , ThomsenPE, H⊘jbergSet al. A comparison of single-lead atrial pacing with dual-chamber pacing in sick sinus syndrome . Eur. Heart J.32 ( 6 ), 686 – 696 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Bardy GH , LeeKL, MarkDBet al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure . N. Engl. J. Med.352 ( 3 ), 225 – 237 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Bogale N , WitteK, PrioriSet al. The European cardiac resynchronization therapy survey: comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades . Eur. J. Heart Fail.13 ( 9 ), 974 – 983 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Mangrolia N , NayarV, PughPJ . Managing anticoagulation in patients receiving implantable cardiac devices . Future Cardiol.8 ( 3 ), 393 – 411 ( 2012 ).
   PubMedGoogle Scholar
• Sticherling C , MartinF, BirnieDet al. Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS) . Europace17 ( 8 ), 1197 – 1214 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Zaca V , MarcucciR, ParodiGet al. Management of antithrombotic therapy in patients undergoing electrophysiological device surgery . Europace17 ( 6 ), 840 – 854 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Reynolds MR , CohenDJ, KugelmassADet al. The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators . J. Am. Coll. Cardiol.47 ( 12 ), 2493 – 2497 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Mahapatra S , BybeeKA, BunchTJet al. Incidence and predictors of cardiac perforation after permanent pacemaker placement . Heart Rhythm2 ( 9 ), 907 – 911 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Wiegand UK , LeJeuneD, BoguschewskiFet al. Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and perioperative antiplatelet/anticoagulation therapy . Chest126 ( 4 ), 1177 – 1186 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Dasgupta A , MontalvoJ, MdendorpSet al. Increased complication rates of cardiac rhythm management devices in ESRD patients . Am. J. Kidney Dis.49 ( 5 ), 656 – 663 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Birnie DH , HealeyJS, WellsGAet al. Pacemaker or defibrillator surgery without interruption of anticoagulation . N. Engl. J. Med.368 ( 22 ), 2084 – 2093 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ghanbari H , PhardWS, Al-AmeriHet al. Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices . Am. J. Cardiol.110 ( 10 ), 1482 – 1488 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Bernard ML , ShotwellM, NietertPJ, GoldMR . Meta-analysis of bleeding complications associated with cardiac rhythm device implantation . Circ. Arrhythm. Electrophysiol.5 ( 3 ), 468 – 474 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Poole JE , GlevaMJ, MelaTet al. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry . Circulation122 ( 16 ), 1553 – 1561 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Lekkerkerker JC , van NieuwkoopC, TrinesSAet al. Risk factors and time delay associated with cardiac device infections: Leiden device registry . Heart95 ( 9 ), 715 – 720 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Klug D , BaldeM, PavinDet al. Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study . Circulation116 ( 12 ), 1349 – 1355 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Carlson MD , FreedmanRA, LevinePA . Lead perforation: incidence in registries . Pacing Clin. Electrophysiol.31 ( 1 ), 13 – 15 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Camm AJ , LipGYH, De CaterinaRet al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation . Eur. Heart J.33 ( 21 ), 2719 – 2747 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• AlTurki A , ProiettiR, BirnieDH, EssebagV . Management of antithrombotic therapy during cardiac implantable device surgery . J. Arrhythm.32 ( 3 ), 163 – 169 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• CHADSVASC . www.chadsvasc.org .
   Google Scholar
• Poldermans D , BaxJJ, BoersmaEet al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA) . Eur. J. Anaesthesiol.27 ( 2 ), 92 – 137 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Blacker DJ , WijdicksEF, McClellandRL . Stroke risk in anticoagulated patients with atrial fibrillation: the Atrial Fibrillation Investigators . Stroke40 ( 4 ), 1410 – 1416 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Weiss P , SoffGA, HalkinH, SeligsohnU . Decline of protein C and S and factors II, VII, IX, X during the initiation of warfarin therapy . Throm. Res.45 ( 6 ), 783 – 790 ( 1987 ).
   PubMed Web of Science ®Google Scholar
• Cannegieter SC , RosendaalFR, BrietE . Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses . Circulation89 ( 2 ), 635 – 641 ( 1994 ).
   PubMed Web of Science ®Google Scholar
• Vahanian A , AlfieriO, AndreottiFet al. ESC Guidelines on the management of valvular heart disease (version 2012) . Eur. Heart J.33 ( 19 ), 2451 – 2496 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Butchart EG , IonescuA, PayneN, GiddingsJ, GrunkemeierGL, FraserAG . A new scoring system to determine thromboembolic risk after heart valve replacement . Circulation108 ( 1 ), 68 – 74 ( 2003 ).
   Google Scholar
• Castellucci LA , CameronC, GalGLet al. Safety and efficacy outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis . BMJ347, f5133 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kearon C , HirshJ . Management of anticoagulation before and after elective surgery . N. Engl. J. Med.336 ( 21 ), 1506 – 1511 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Roy P , BonelloL, TorgusonRet al. Temporal relation between clopidogrel cessation and stent thrombosis after drug-eluting stent implantation . Am. J. Cardiol.103 ( 6 ), 801 – 805 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Schulz S , SchusterT, MehilliJet al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period . Eur. Heart J.30 ( 22 ), 2714 – 2721 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Eisenberg MJ , RichardPR, LibersanD, FilionKB . Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents . Circulation119 ( 12 ), 1634 – 1642 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Sarno G , LagerqvistB, FröbertO, NilssonJet al. Lower risk of stent thrombosis and restenosis with unrestricted use of ‘new-generation’ drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR) . Eur. Heart J.33 ( 5 ), 606 – 613 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Park KW , KangSH, VeldersMAet al. Safety and efficacy of everolimus- versus sirolimus-eluting stents: a systematic review and meta-analysis of 11 randomized trials . Am. Heart J.165 ( 2 ), 241 – 250 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Palmerini T , Biondi-ZoccaiG, Della RivaDet al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis . Lancet379 ( 9824 ), 1393 – 1402 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Ferreira-Gonzalez I , MarsalJR, RiberaAet al. Double antiplatelet therapy after drug-eluting stent implantation: risk associated with discontinuation within the first year . J. Am. Coll. Cardiol.60 ( 15 ), 1333 – 1339 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Mehran R , BaberU, StegPGet al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2year results from a prospective observational study . Lancet382 ( 9906 ), 1714 – 1722 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Scheller B . Antithrombocytic therapy and PCI. Duration of therapy after DCB/stents/scaffolds . Herz39 ( 7 ), 819 – 821 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Windecker S , KolhP, AlfonsoFet al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) . Eur. Heart J.35 ( 37 ), 2541 – 2619 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Douketis JD , SpyropoulosAC, SpencerFAet al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th Edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines . Chest141 ( 2 ), 326 – 350 ( 2012 ).
   Web of Science ®Google Scholar
• Douketis JD , BergerPB, DunnASet al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) . Chest133 ( 6 ), 299 – 339 ( 2008 ).
   Google Scholar
• Robinson M , HealeyJS, EikelboomJet al. Postoperative low-molecular-weight heparin bridging is associated with an increase in wound hematoma following surgery for pacemakers and implantable defibrillators . Pacing Clin. Electrophysiol.32 ( 3 ), 378 – 382 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Tolosana JM , BerneP, MontLet al. Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thrombo-embolic events: oral anticoagulation or bridging with intravenous heparin? A prospective randomized trial . Eur. Heart J.30 ( 15 ), 1880 – 1884 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Cheng A , NazarianS, BrinkerJAet al. Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation: a randomized clinical trial . Heart Rhythm8 ( 4 ), 536 – 540 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Sant’anna RT , LeiriaTL, NascimentoTet al. Meta-analysis of continuous oral anticoagulants versus heparin bridging in patients undergoing CIED surgery: reappraisal after the BRUISE study . Pacing Clin. Electrophysiol.38 ( 4 ), 417 – 423 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Yang X , WangZ, ZhangYet, YinX, HouY . The safety and efficacy of antithrombotic therapy in patients undergoing cardiac rhythm device implantation: a meta-analysis . Europace17 ( 7 ), 1076 – 1084 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Siegal D , YudinJ, KaatzS, DouketisJD, LimW, SpyropoulosAC . Periprocedual heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates . Circulation126 ( 13 ), 1630 – 1639 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Proietti R , PortoI, LeviMet al. Risk of pocket haematoma in patients on chronic anticoagulation with warfarin undergoing electrophysiological device implantation: a comparison of different peri-operative management strategies . Eur. Rev. Med. Pharmacol. Sci.19 ( 8 ), 1461 – 1479 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Feng L , LiY, LiJ, YuB . Oral anticoagulation continuation compared with heparin bridging therapy among high risk patients undergoing implantation of cardiac rhythm devices . Thromb. Haemost.108 ( 6 ), 1124 – 1131 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Douketis JD , SpyropoulosAC, KaatzSet al. Perioperative bridging anticoagulation in patients with atrial fibrillation . N. Engl. J. Med.373 ( 9 ), 823 – 833 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Coyle D , CoyleK, EssebagVet al. Cost effectiveness of continued-warfarin versus heparin-bridging therapy during pacemaker and defibrillator surgery . J. Am. Coll. Cardiol.65 ( 9 ), 957 – 959 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Harder S , GraffJ . Novel oral anticoagulants: clinical pharmacology, indications and practical considerations . Eur. J. Clin. Pharmacol.69 ( 9 ), 1617 – 1633 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Heidbuchel H , VerhammeP, AlingsMet al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation . Europace17 ( 10 ), 1467 – 507 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Healey JS , EikelboomJ, DouketisJet al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial . Circulation126 ( 3 ), 343 – 348 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Rowley CP , BernardML, BrabhamWWet al. Safety of continuous anticoagulation with dabigatran during implantation of cardiac rhythm devices . Am. J. Cardiol.111 ( 8 ), 1165 – 1168 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Jennings JM , RobichauxR, McelderryHTet al. Cardiovascular implantable electronic device implantation with uninterrupted dabigatran: comparison to uninterrupted warfarin . J. Cardiovasc. Electrophysiol.24 ( 10 ), 1125 – 1129 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kosiuk J , KoutalasE, DoeringMet al. Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations . Europace16 ( 7 ), 1028 – 1032 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Shivanshu M , MuthusamyP, MowersKLet al. Safety of anticoagulation with uninterrupted warfarin vs. interrupted dabigatran in patients requiring an implantable cardiac device . Cardiovasc. Diagn. Ther.6 ( 1 ), 3 – 9 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Nascimento T , BirnieDH, HealeyJSet al. Managing novel oral anticoagulants in patients with atrial fibrillation undergoing device surgery: Canadian survey . Can. J. Cardiol.30 ( 2 ), 231 – 236 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Tompkins C , ChengA, DalalDet al. Dual antiplatelet therapy and heparin “bridging” significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation . J. Am. Coll. Cardiol.55 ( 21 ), 2376 – 2382 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Cano O , OscaJ, Sancho-TelloMJ, OlagueJ, CastroJE, SalvadorA . Morbidity associated with three different antiplatelet regimens in patients undergoing implantation of cardiac rhythm management devices . Europace13 ( 3 ), 395 – 401 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Said SM , EspererHD, HahnJet al. Influence of oral antiplatelet therapy on hemorrhagic complications of pacemaker implantation . Clin. Res. Cardiol.102 ( 5 ), 345 – 349 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Dai Y , ChenKP, HuaW, ZhangJT, ZhangS . Dual antiplatelet therapy increases pocket hematoma complications in Chinese patients with pacemaker implantation . J. Geriatr. Cardiol.12 ( 4 ), 383 – 387 ( 2015 ).
   PubMedGoogle Scholar
• Przybylski A , DerejkoP, KwasniewskiWet al. Bleeding complications after pacemaker or cardioverter-defibrillator implantation in patients receiving dual antiplatelet therapy . Neth. Heart J.18 ( 5 ), 230 – 235 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Lip GY , WindeckerS, HuberKet al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS) . Eur. Heart J.35 ( 45 ), 3155 – 3179 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Calkins S , WillemsS, GerstenfeldEPet al. Uninterrupted dabigatran versus warfarin for ablation in Atrial Fibrillation . N. Engl. J. Med.376 ( 17 ), 1627 – 1636 ( 2017 ).
   PubMed Web of Science ®Google Scholar